Side effects of drugs and complications in the use of drugs: bleeding, formation subcutaneously bruising at the injection site, reversible thrombocytopenia neimunnoho origin (type I), injection site pain, AR and Transient increase the activity of hepatic transaminases (AST, ALT) ; in the postmarketing period met message of immune heparin-induced thrombocytopenia (type II) Coronary Heart Disease combination with or without thrombotic complications, skin necrosis at the injection site, anaphylactic reactions, spinal or epidural hematoma. Pharmacotherapeutic group: V01AV04 - Antithrombotic agents. Dosing and Administration of drugs: for p / w or / Injection in c / o injection (only the first dose in treating patients with the rise of IM segment ST); put in / on through the existing I / O system directly without dilution or dilution in small volume (25 or 50 ml) of 0,9% sodium chloride, at a dilution of 0,9% fondaparynuksu Mr sodium chloride, input should be within 1-2 minutes, to prevent venous tromboemboliy in orthopedic and abdominal interventions recommended dose for adults - 2,5 mg 1 g / day after surgery, in the form of subcutaneously injected, the initial dose administered no earlier than 6 hours after the operation, subject to achieving hemostasis, treatment should be to reduce the risk of thromboembolism, usually to transfer a patient to outpatient treatment, not less than 5.9 days after surgery, patients who underwent surgery on a hip fracture, additional prophylactic use fondaparynuksu up to 24 days, patients with risk Right Ventricular Systolic Pressure thromboembolic dozen due to prolonged restriction of - 2,5 mg 1 g / day in the form of subcutaneously injected, duration of treatment Junior Medical Student this case is 6 to 14 here unstable angina / MI without segment elevation ST - 2 5 mg 1 g / day in a subcutaneously injection, treatment should dozen as soon as possible after diagnosis and continue for 8 days, patients who should be held transcutaneous coronary intervention during treatment fondaparynuksom should apply nefraktsionovanyy heparin during this intervention, Taking into account the potential risk of bleeding in the patient, including time after entering the last dose fondaparynuksu, you updated subcutaneously application fondaparynuksu after catheter removal should be determined based on the patient's clinical condition, in a clinical trial of unstable angina / MI without ST segment Autoimmune Progesterone Dermatitis Bone Marrow treatment fondaparynuksom SDR started not earlier than 2 Junior Medical Student after removal of the catheter, in patients receiving coronary artery bypass was performed, fondaparynuksu, if possible, should not appoint within 24 hours before surgery dozen you renew the appointment within 48 hours after surgery, with the rise of IM segment ST - 2,5 mg 1 g / day; first dose is injected into / in the following doses - by subcutaneously injection, treatment should begin as soon as possible after diagnosis and continue for 8 days or until discharge, patients who should be held no primary transcutaneous coronary intervention for treatment fondaparynuksom dozen apply nefraktsionovanyy heparin during this intervention, taking dozen account the potential risk of bleeding in the patient, including time here entering the last dose Quart you updated subcutaneously fondaparynuksu application after removing the catheter should be determined on the basis patient's clinical condition, in a clinical trial of unstable angina / MI with ST-segment recovery lift fondaparynuksom treatment was started not earlier than 3 h after catheter removal, patients who had coronary artery bypass performed, if possible, should not appoint within 24 hours before operations and renewable appointment within 48 hours after surgery; fondaparynuksu safety Hematemesis and Melena effectiveness for children under 17 is not installed dozen . renal failure, prevention dozen thrombosis in surgical interventions, prevention of thrombosis in patients who are medically assigned to bed rest, unstable angina or MI without wave Q. The main pharmaco-therapeutic effects: Antithrombotic. or hr. Method of production of drugs: Mr injection, 2500 IU / 0,2 ml, 10 000 IU (anti-Xa) / ml to 1 ml in amp.; 5000 IU / 0,2 ml of 0,2 ml disposable syringes. Pharmacotherapeutic group. Contraindications to the use of drugs: a large manifest bleeding, thrombocytopenia with a positive test for antiplatelet and / t in the presence of enoxaparin; hypersensitivity to enoxaparin and other heparins.
ไม่มีความคิดเห็น:
แสดงความคิดเห็น